|
|
|
| Comparative Observation of the Clinical Efficacy of the Same Scheme in the Treatment of Simple Pulmonary Tuberculosis and Pulmonary Tuberculosis with Diabetes |
| Zhong Bing1, Jiao Jie2, Li Fangfei1, Lin Biding1,* |
1. Department of infectious diseases,Fuding City Hospital,Fujian 355200; 2. Respiratory Department of Fuding Hospital,Fuding 355200,Fujian |
|
|
|
|
Abstract Objective To compare the therapeutic effects of the same antituberculosis methods on simple pulmonary tuberculosis and pulmonary tuberculosis with diabetes,so as to provide corresponding reference for clinical treatment scheme selection. Methods 120 patients with pulmonary tuberculosis were selected and divided into group A(75 cases) with simple pulmonary tuberculosis according to whether they have diabetes or not;45 patients in group B with pulmonary tuberculosis and diabetes.In terms of treatment method selection,both groups of patients were intervened with the 2RHZE/4HR anti tuberculosis treatment regimen,which lasted for 6 months.Compare the efficacy,sputum conversion,immune function,and adverse reaction indicators of two groups of research subjects. Results After 6 months of intervention,there was no significant difference in the total effective rate of treatment between the observation group and the control group (89.33% vs 91.11%,P>0.05).The sputum conversion rates after 1 month,3 months,and 6 months of treatment were 72.00%,85.33%,and 94.67% in the observation group,and 40.00%,48.89%,and 66.67% in the control group,respectively.The sputum conversion rates in the observation group were higher than those in the control group at different stages after treatment(P<0.05).After 6 months of treatment,the peripheral blood T lymphocyte subsets CD3+,CD4+,CD4+/CD8+in both groups of patients increased,while CD8+decreased.The changes in these indicators were more significant in the observation group compared to the control group(P<0.05).There was no significant difference in adverse reactions between the comparison groups(P>0.05). Conclusion The same antituberculosis program intervenes in pulmonary tuberculosis with simple or combined diabetes,and the treatment effect is different.In diabetes,the antituberculosis drug intervention has poor effect on sputum bacteria negative,and at the same time,the improvement of immune function is poor.Therefore,in practice,it is necessary to cooperate with certain blood glucose control when treating pulmonary tuberculosis with diabetes,and then combine the antituberculosis program intervention to achieve good treatment effect.
|
|
Received: 19 May 2025
|
|
|
|
|
|
[1] 周丽红. 优化方案治疗复治肺结核合并糖尿病的效果分析[J].中国医药指南,2020,18(1):72-73. [2] 孙婷婷,郭春辉,翁锡定,等.左氧氟沙星联合胰岛素强化治疗肺结核合并糖尿病的效果观察[J].医学理论与实践,2019,32(17):2684-2686. [3] 陈志飞,刘妍丽,连展.糖尿病合并肺结核患者血糖控制水平与抗结核疗效的关系研究[J].中国医药导报,2019,16(26):133-136. [4] 陈汉钦. 糖尿病合并肺结核患者的临床症状与疗效[J].中国民康医学,2019,31(21):129-130. [5] 中华医学会.肺结核基层诊疗指南(2018年)[J].中华全科医师杂志,2019,18(008):709-717. [6] 中华医学会糖尿病学分会,国家基层糖尿病防治管理办公室.国家基层糖尿病防治管理指南(2018)[J].中华内科杂志,2018,57(12):885-893. [7] 秦科宇,高亮.60例肺结核合并糖尿病患者的临床分析[J].中国继续医学教育,2018,10(6):70-72. [8] 郭晶,庞加磊,高卫卫,等.2019-2021年南京地区成人活动性肺结核合并糖尿病患者表型耐药特征分析[J].中国防痨杂志,2024,46(1):62-69. [9] 姬淑英. 相同方案治疗单纯性肺结核与肺结核合并糖尿病的临床疗效对照观察[J].中外医药研究,2023,2(19):15-17. [10] 蔡清河,符慧,陈蕊明,等.2016-2022年汕头市肺结核合并糖尿病患者临床特征及其影响因素分析[J].中国防痨杂志,2024,46(08):926-934. [11] 顾玉虹,张雅惠,何刚,等.抗结核固定剂量复合剂(FDC)治疗糖尿病合并肺结核的效果及安全性[J].罕少疾病杂志,2023,30(10):48-49. [12] 王珊珊,浦永兰.肺结核合并2型糖尿病与T淋巴细胞亚群及血糖控制水平相关性分析[J].当代医药论丛,2024,22(24):111-113. [13] 郭兴华. 肺结核合并糖尿病患者糖脂代谢指标与免疫因子,炎性因子水平的相关性分析[J].中国社区医师,2024,40(4):82-84. [14] 杨梁梓,王玉香,谭洁,等.合并糖尿病的药物敏感性肺结核患者治疗强化期痰菌延迟阴转的影响因素分析[J].结核与肺部疾病杂志,2023,4(5):370-375. |
| [1] |
Li Yuan, Deng Xuecong, Wang Mengge, Li Huanhuan, Li Jing, Tian Ling. The Impact of Insulin Combined with Dietary Intervention Therapy on the Lipid Levels and the Incidence of Gestational Complications of Gestational Diabetes Mellitus Patients[J]. journal1, 2025, 45(6): 30-32. |
| [2] |
. [J]. journal1, 2025, 45(6): 78-81. |
| [3] |
. [J]. journal1, 2025, 45(6): 86-88. |
| [4] |
. [J]. journal1, 2025, 45(6): 113-115. |
| [5] |
. [J]. journal1, 2025, 45(6): 137-139. |
| [6] |
. [J]. journal1, 2025, 45(5): 78-80. |
|
|
|
|